Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Basit Öğe Kaydı
dc.authorscopusid57211313828
dc.authorscopusid6701488999
dc.authorscopusid55754179900
dc.authorscopusid57801244000
dc.authorscopusid57224538924
dc.authorscopusid58100171900
dc.authorscopusid57348194400
dc.contributor.authorKaraçın, Cengiz
dc.contributor.authorÖksüzoğlu, Berna
dc.contributor.authorDemirci, Ayşe
dc.contributor.authorKeskinkılıç, Merve
dc.contributor.authorBaytemur, Naziyet Köse
dc.contributor.authorYılmaz, Funda
dc.contributor.authorSelvi, Oğuzhan
dc.contributor.authorKaraboyun, Kubilay
dc.date.accessioned2023-05-06T17:23:34Z
dc.date.available2023-05-06T17:23:34Z
dc.date.issued2023
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Ana Bilim Dalı
dc.description.abstractBackground: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based). Methods: A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and ? 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. Results: The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0–14.0) months in the ET arm of group A, and 5.3 (3.9–6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8–7.7) months in the ET arm of group B, and 5.7 (4.6–6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5–8.0) months in the ET arm of group C and 4.0 (3.5–4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months. Conclusion: Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after first-line CDKi compared to monotherapy ET. © 2023, The Author(s).
dc.description.sponsorshipSpecial thanks to Turkish Oncology Group (TOG) - Breast Cancer Consortium.
dc.identifier.doi10.1186/s12885-023-10609-8
dc.identifier.issn1471-2407
dc.identifier.issue1en_US
dc.identifier.pmid36765293
dc.identifier.scopus2-s2.0-85147894207
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1186/s12885-023-10609-8
dc.identifier.urihttps://hdl.handle.net/20.500.11776/12161
dc.identifier.volume23
dc.identifier.wosWOS:000980043700010
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKaraboyun, Kubilay
dc.language.isoen
dc.publisherBioMed Central Ltd
dc.relation.ispartofBMC Cancer
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAdvanced breast cancer
dc.subjectCyclin-dependent kinase
dc.subjectEndocrine treatment
dc.subjectEverolimus
dc.subjectFulvestrant
dc.subjectHormonotherapy
dc.subjectPalbociclib
dc.subjectRibociclib
dc.subjectcyclin dependent kinase 4
dc.subjectcyclin dependent kinase 6
dc.subjectcyclin dependent kinase inhibitor
dc.subjecteverolimus
dc.subjectfulvestrant
dc.subjectmammalian target of rapamycin
dc.subjectpalbociclib
dc.subjectribociclib
dc.subjectantineoplastic agent
dc.subjectepidermal growth factor receptor 2
dc.subjecteverolimus
dc.subjectprotein kinase inhibitor
dc.subjectadult
dc.subjectadvanced breast cancer
dc.subjectaged
dc.subjectArticle
dc.subjectcancer chemotherapy
dc.subjectcancer combination chemotherapy
dc.subjectcancer growth
dc.subjectcancer therapy
dc.subjectcontrolled study
dc.subjectdrug efficacy
dc.subjectdrug use
dc.subjecthormonal therapy
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmonotherapy
dc.subjectpatient care
dc.subjectphysician
dc.subjectprogression free survival
dc.subjectretrospective study
dc.subjectsurvival analysis
dc.subjecttreatment duration
dc.subjectbreast tumor
dc.subjectdisease exacerbation
dc.subjectfemale
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectBreast Neoplasms
dc.subjectDisease Progression
dc.subjectEverolimus
dc.subjectFemale
dc.subjectFulvestrant
dc.subjectHumans
dc.subjectProtein Kinase Inhibitors
dc.subjectReceptor, ErbB-2
dc.titleEfficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
12161.pdf
Boyut:
1.52 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu